Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in leydig cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 9 Parkinson's papers of 1,077 | 0.70 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 2615
Sealed predictions
- ARX in dopamine neurons, braak-0.30 (p 0.428) → +0.04 (p 0.912)receipt 2622
Swarm cases
receipt 2622: ARX in dopamine neurons, braak
- power
- full sample -0.01 (p 0.983, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.16 (p 0.521, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.20 (p 0.434, n 18). could be the mix.
- skeptic
- leave-one-out range -0.11 to +0.11, sign flips 8; without severely affected donors -0.01 (p 0.983, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ARX in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts